Objective
During this RISE project we aim to develop nanoparticle-based encapsulated libraries of different immunotherapeutic
biomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art for the
management of cancer starts with surgery, after identification of an accessible tumour mass. Surgery remains an effective
treatment option for many types of cancer today and it is considered curative treatment for most solid tumours. It forms part
of a multidisciplinary approach used in conjunction with radiotherapy or chemotherapy. These approaches, however, have
several limitations, including inability of surgical resection to affect distal metastatic disease, toxicity to healthy tissues with
chemotherapy and lack of effectiveness of radiation therapy in more aggressive tumours. The observation that cancer can
relapse months or years after initial surgery implies that micrometastases still resides within the body in a latent state. Our
proposal is to take cancer therapy to beyond state-of-art by implementing techniques which will take us into new directions.
This includes a) new methods to identify immune gene profiles and biomarkers b) transgenic mouse models where the
complex interactions that underlie immune function can be visualised as multiplexed events in real time and c) the use of
nanoparticle-based libraries of immune modulating reagent combinations. There are three key objectives within this project:
i) to use immune gene signatures to monitor disease progression and therapeutic efficacy of immunotherapy combinations
on nanoparticle-based platforms, ii) to optimise the platform to encapsulate libraries of immune components for more
personalised, accurate and timely delivery of the payload to its intended target and iii) to optimise the overall cancer
management process of image-guided surgery followed by postoperative immunotherapy so that we can ultimately provide a
lifetime of protection against cancer.
Fields of science
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- medical and health sciencesclinical medicinesurgery
- natural sciencesbiological sciencesbiochemistrybiomolecules
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Programme(s)
Coordinator
Participation ended
2573 HT 's-Gravenhage (Den Haag)
Netherlands
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participants (18)
Participation ended
2333 ZA Leiden
See on map
3015 GD Rotterdam
See on map
2628 CN Delft
See on map
62032 Camerino
See on map
84036 Landshut
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1012WX Amsterdam
See on map
S10 2TN Sheffield
See on map
6200 MD Maastricht
See on map
07745 Jena
See on map
50931 Koln
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
00045 Genzano Di Roma
See on map
67659 Kaiserslautern
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
00072 Ariccia
See on map
00040 Rocca Di Papa
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
SE1 0BL London
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
31-007 Krakow
See on map
Participation ended
00074 Nemi
See on map
SE1 0BL London
See on map